AboutMission & Vision
Telesis Pharma BV is a pharmaceutical company working on the processes and chemistry of drugs. We are developing improved drug synthesis to reduce costs significantly while maintaining the high quality standards. This way we help our customers offer highly competitive drug products and therefore contribute to the accessibility of medicine to all.
It is Telesis aim to become a recognized drug synthesis company through ‘building’ on the current state-of-the-art MCR know-how and related licensed IP. Being an important link in the chain ‘from raw materials to marketed drug’ Telesis is focused on co-maker- and partnership relations. Telesis will commit to the highest environmental and quality standards.
With a highly motivated and competent team Telesis wants to expand the company after the adaptation of its first drug process in the market by hiring additional people and working on subsequent classes of drugs. The technology oriented organization strives to a complementary skilled team to further expand the possibilities of the MCR technology and to optimize return of investment for all stakeholders.
High-end Generic Drug Market
Following an analysis of the Telesis technology proposition and the pharma market environment it is decided by the Telesis team to focus it’s initially commercialization efforts on the ‘high-end’ generic drug market.
Fee for Service
Telesis also wants to explore its capabilities in an earlier phase to reduce the dependence on (long-term) external financing. Within its primarily focal area Telesis will seek for commercial partners’ interest in a full or partial role for its MCR technology applicable to the partners’ molecule of choice. This way projects can be generated with on the bases a ‘fee for service’ structure and potential future income from tech transfer, royalties or else. In this respect it is important to have access to a kg scale facility. This is part of Telesis defined strategy.
Drug Discovery Developments
Telesis capabilities and IP assets could also be used in drug discovery developments utilizing the versatility of scaffolds following the two-way use of MCR technology. This may bring Telesis ‘on board’ of next generation medicine and associated processes to manufacture these drugs.